This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $406,051 to the University of Oregon to conduct research on the genetic and molecular mechanisms of psychedelic compounds and their effects on neuroplasticity and behavior in the model organism C. elegans. The overarching goal is to determine the degree of polypharmacology - the ability to interact with multiple biological targets - of...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to examine the effects of psilocybin on brain function, cognition, and behavior in individuals with opioid use disorder (OUD). The $1,462,135 award will support a two-phase study over a 24-month period starting on Jul 1, 2024. In the initial R61 phase, the study will prospectively assign 72 OUD participants to receive...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the brain mechanisms underlying the therapeutic potential of psilocybin, a psychoactive compound, for treating conditions such as anxiety, depression, addiction, and pain. The $246,000 grant, awarded on June 15, 2025, will support research at Princeton University to explore psilocybin's effects on behavioral states, motivated...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $237,000 to the University of California, San Diego (UCSD) to develop translational depression-relevant models in mice. The goal is to better evaluate the efficacy of psychedelic agents, such as psilocybin, in reversing depression-relevant amotivated behaviors and identifying associated electroencephalographic (EEG) biomarkers. Specifically, the...
This Project Grant award, with a total funding amount of $679,118, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The grant supports research to understand the cellular and circuit mechanisms by which the psychedelic compound psilocybin can rescue the deleterious effects of stress on the brain. The research aims to determine psilocybin's acute and enduring effects on synaptic plasticity, cortical functional...
The federal Project Grant award F99NS139512, with $130,722.00 in funding, was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant supports research at The Washington University in St. Louis to investigate the effects of psychedelics on brain function and neuroplasticity. Specifically, the research aims to determine whether short-duration versus long-duration psychedelics differentially impact...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The $627,945 award to Cornell University will fund a 5-year study to determine how psilocybin administration affects the activity of the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex. The researchers will use...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 in funding to New York University School of Medicine to evaluate the use of psilocybin as an adjunctive treatment for opioid use disorder (OUD) in patients on methadone maintenance who continue to use illicit opioids. The project will recruit 240 participants across 4 opioid treatment programs, providing a single dose of...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating the role of the glucocorticoid receptor (GR) as a neuromolecular mechanism regulating inhibitory control processes, such as reward sensitivity and rash impulsivity, which contribute to maladaptive behaviors associated with substance use disorders. The $127,635 award, which runs from June 2025 to December 2025, will employ...
The federal Project Grant award R01AA031417, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) program, supports a mechanistic study investigating the neural effects of psilocybin-assisted treatment for alcohol use disorder (AUD). The $708,511 award to New York University School of Medicine will conduct a randomized controlled trial examining the impact of high-dose versus low-dose psilocybin on neural response to alcohol...
This Project Grant award for $222,254 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to examine the effects of psychedelic 5-HT2A agonist drugs like DOI and psilocybin on food-seeking behavior and reward circuit function in a rat model of early-life adversity. The objective is to determine if these psychedelic drugs can persistently reverse the alterations in reward processing induced by early-life adversity in this translationally relevant animal model. The research will also investigate whole-brain regional activity associated with the aberrant reward-seeking behaviors and their reversal by psychedelics, with the goal of developing a new animal model to study the therapeutic mechanisms of 5-HT2A receptor stimulation. This project, running from August 2024 to June 2027, aims to contribute to the basic research on psychedelic drug effects and provide insights for developing more effective yet minimally disruptive therapeutic strategies for disorders involving dysregulated reward circuitry.